New injection shows promise in slowing devastating nerve disease

NCT ID NCT03759379

Completed Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new drug called vutrisiran could help people with hereditary transthyretin amyloidosis (hATTR), a rare disease where a faulty protein builds up and damages nerves and organs. 164 patients received injections of either vutrisiran or an existing treatment, and their results were compared to a separate group of patients who received a placebo. The main goal was to see if vutrisiran could slow or stop the worsening of nerve damage, improve walking ability, and enhance quality of life over 18 months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Trial Site

La Mesa, California, 91942, United States
Clinical Trial Site

Aurora, Colorado, 80045, United States
Clinical Trial Site

Jacksonville, Florida, 32224, United States
Clinical Trial Site

Chicago, Illinois, 60611, United States
Clinical Trial Site

Fairway, Kansas, 66205, United States
Clinical Trial Site

Baltimore, Maryland, 21224, United States
Clinical Trial Site

Boston, Massachusetts, 02118, United States
Clinical Trial Site

Rochester, Minnesota, 55902, United States
Clinical Trial Site

St Louis, Missouri, 63130, United States
Clinical Trial Site

New York, New York, 10032, United States
Clinical Trial Site

Chapel Hill, North Carolina, 27599, United States
Clinical Trial Site

Columbus, Ohio, 43210, United States
Clinical Trial Site

Portland, Oregon, 97239, United States
Clinical Trial Site

Philadelphia, Pennsylvania, 19104, United States
Clinical Trial Site

Dallas, Texas, 75246, United States
Clinical Trial Site

Buenos Aires, C1428AQK, Argentina
Clinical Trial Site

Northmead, New South Wales, NSW 2152, Australia
Clinical Trial Site

Brisbane, Queensland, 4102, Australia
Clinical Trial Site

Melbourne, Victoria, 3128, Australia
Clinical Trial Site

Brussels, 1070, Belgium
Clinical Trial Site

Leuven, 3000, Belgium
Clinical Trial Site

Rio de Janeiro, CEP21941, Brazil
Clinical Trial Site

Sofia, 1431, Bulgaria
Clinical Trial Site

Montreal, H3A 2B4, Canada
Clinical Trial Site

Vancouver, V5Z 1M9, Canada
Clinical Trial Site

Nicosia, 2371, Cyprus
Clinical Trial Site

Bordeaux, 33076, France
Clinical Trial Site

Créteil, 94000, France
Clinical Trial Site

Le Kremlin-Bicêtre, 94270, France
Clinical Trial Site

Lille, 59037, France
Clinical Trial Site

Marseille, 13005, France
Clinical Trial Site

Nantes, 44093, France
Clinical Trial Site

Heidelberg, 69120, Germany
Clinical Trial Site

Mainz, 55131, Germany
Clinical Trial Site

Münster, 48149, Germany
Clinical Trial Site

Athens, 11528, Greece
Clinical Trial Site

Messina, 98100, Italy
Clinical Trial Site

Milan, 20133, Italy
Clinical Trial Site

Pavia, 27100, Italy
Clinical Trial Site

Rome, 00168, Italy
Clinical Trial Site

Kumamoto, 860-8556, Japan
Clinical Trial Site

Nagano, 390-8621, Japan
Clinical Trial Site

Nagoya, 466-8560, Japan
Clinical Trial Site

Osaka, 565-0871, Japan
Clinical Trial Site

Kuala Lumpur, 59100, Malaysia
Clinical Trial Site

Mexico City, Mexico City, 14080, Mexico
Clinical Trial Site

Groningen, 9713 AP, Netherlands
Clinical Trial Site

Lisbon, 1649-035, Portugal
Clinical Trial Site

Porto, 4099-001, Portugal
Clinical Trial Site

Daegu, 41944, South Korea
Clinical Trial Site

Seoul, 05030, South Korea
Clinical Trial Site

Seoul, 06351, South Korea
Clinical Trial Site

Barcelona, 08035, Spain
Clinical Trial Site

Hospitalet de Llobregat (Barcelona), 08907, Spain
Clinical Trial Site

Huelva, 21005, Spain
Clinical Trial Site

Madrid, 28040, Spain
Clinical Trial Site

Madrid, 28222, Spain
Clinical Trial Site

Valencia, 46026, Spain
Clinical Trial Site

Solna, SE-171 64, Sweden
Clinical Trial Site

Umeå, 907 37, Sweden
Clinical Trial Site

Taipei, 100, Taiwan
Clinical Trial Site

Taipei, 11217, Taiwan
Clinical Trial Site

Taoyuan, 333, Taiwan
Clinical Trial Site

London, NW3 2QG, United Kingdom

Conditions

Explore the condition pages connected to this study.

AMYLOIDOSIS, HEREDITARY TRANSTHYRETIN AMYLOIDOSIS